Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Summary

This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.

Timeline

Start

2025-08-18

Primary completion

2028-09-30

Completion

2030-09-30

Drugs

Indications